Cuprina Holdings (Cayman) Limited

What they do

Cuprina develops and commercializes chronic wound care products, primarily MEDIFLY, a biological debridement tool used in Maggot Debridement Therapy as an alternative to surgical debridement. It has sold MEDIFLY in Singapore since February 2020 and in Hong Kong since March 2023, selling mainly to public and private hospitals and clinics where patients obtain products by physician prescription. It also sells three cosmeceutical products introduced in 2023 — a hydrating balm, a muscle energy cream and a pain relief muscle patch — through retailers, gyms and online platforms.

Revenue drivers

• MEDIFLY chronic wound care — Commercialized biological debridement product sold mainly to public and private hospitals and clinics in Singapore, and in Hong Kong since March 2023; this is the company's core commercialized offering.
• Cosmeceuticals — Three products introduced in 2023 (hydrating balm, muscle energy cream, pain relief muscle patch), made by commissioned OEM skincare manufacturers and sold direct to consumers via retailers, gyms and online platforms in Singapore, Malaysia and Australia.
• Pipeline wound care (pre-revenue) — Bullfrog-collagen dressings (sponges, particles, hydrogels) and medical-leech wound treatment products are in development, with commercialization targeted for 2026-2028 subject to regulatory approval.

Recent performance

Annual revenue was $38,789 in 2025 versus $35,522 in 2024, a very small base. Net loss widened to $3.6 million in 2025 from $1.1 million in 2024, while diluted EPS improved to -$1.42 from -$6.38. Operating cash flow was -$7.1 million in 2025 compared with -$908,609 in 2024. At December 31, 2025, total assets were $6.6 million, total liabilities $2.7 million, shareholders' equity $3.9 million and cash and equivalents $2.4 million.

Strategy

Management says it plans to expand sales and establish physical operations in the Middle East, particularly Gulf Cooperation Council member states, and mainland China during 2026 and 2027. It expects to develop its two pipeline wound care lines — bullfrog-collagen dressings and medical-leech products — over 2026 and 2027, targeting commercial availability subject to regulatory approval. It also plans to explore cosmeceutical candidates incorporating bullfrog collagen using collagen production technology under development, with possible commercialization between 2026 and 2028.

Risks

• Very small revenue base — 2025 revenue of $38,789 is far below the $3.6 million net loss, so the business is not yet self-funding at scale.
• Widening losses and cash burn — Net loss widened to $3.6 million and operating cash outflow to $7.1 million in 2025, against $2.4 million of cash at year-end.
• Regulatory and development risk — Pipeline products (bullfrog-collagen dressings, medical-leech treatments, collagen cosmeceuticals) require regulatory approval and may not reach the targeted 2026-2028 commercialization windows.
• Geographic concentration and expansion execution — Sales are primarily in Singapore with Hong Kong added in 2023, so planned Middle East and mainland China expansion depends on new market entry that has not yet been established.

Outlook

Management states it has strategic plans for 2026 and 2027 to expand sales and establish physical operations in the GCC and mainland China. It expects pipeline chronic wound care products to be developed over 2026 and 2027 and to become commercially available subject to regulatory approval. It also targets possible commercialization of bullfrog-collagen cosmeceutical candidates between 2026 and 2028, depending on R&D progress.